Acrivon Therapeutics (ACRV)
Develops cancer therapies and companion diagnostics around drug-specific proteomic patient selection.
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy?
Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) were up 3.2% on Monday. The stock traded as high as $1.64 and last traded at $1.61. Approximately 865,467 shares traded hands during trading, an increase of 47% from the average daily volume of 589,292 shares. The stock had previously closed at $1.56. Analysts
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ: ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-breaking presentation at a major oncology meeting by Dana-Farber's Panagiotis Konstantinopoulos, with data reviewed on
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update
Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) saw a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 2,024,627 shares, a decrease of 73.1% from the January 15th total of 7,521,144 shares. Approximately 7.0% of the shares of the company are sold short. Based
Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock
Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) CFO Adam Levy purchased 8,832 shares of the firm's stock in a transaction on Wednesday, January 14th. The shares were purchased at an average cost of $1.70 per share, with a total value of $15,014.40. Following the completion of the transaction, the chief financial officer owned 20,983
Acrivon Therapeutics (NASDAQ:ACRV) CEO Acquires $82,320.00 in Stock
Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) CEO Peter Blume-Jensen purchased 49,000 shares of the business's stock in a transaction on Wednesday, January 14th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $82,320.00. Following the completion of the transaction, the chief executive officer directly owned
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls
Acrivon Therapeutics Inc. (NASDAQ: ACRV) on Thursday shared updates regarding the Phase 2 ACR-368 program and initial clinical data from the ACR-2316 Phase 1 study.
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash equivalents and marketable securities of $134.4 million as of September 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights.
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
Acrivon Therapeutics, Inc. (ACRV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)
The heavy selling pressure might have exhausted for Acrivon Therapeutics, Inc. (ACRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks
Acrivon Therapeutics, Inc. (ACRV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic cancers. The pipeline updates indicate progress in clinical trials, enhancing the potential for successful outcomes in targeted cancer treatments. Financially, Acrivon is well-positioned with sufficient funding to advance its pipeline, though risks remain inherent in biotech investments.